Communications Biology (Nov 2024)

KLF13 promotes SLE pathogenesis by modifying chromatin accessibility of key proinflammatory cytokine genes

  • Andrew Wang,
  • Anna-Marie Fairhurst,
  • Kui Liu,
  • Benjamin Wakeland,
  • Spencer Barnes,
  • Venkat S. Malladi,
  • Kasthuribai Viswanathan,
  • Carlos Arana,
  • Igor Dozmorov,
  • Amrita Singhar,
  • Yong Du,
  • Marjaan Imam,
  • Angela Moses,
  • Christian Chen,
  • Ashwini Sunkavalli,
  • Jose Casco,
  • Dinesh Rakheja,
  • Quan-Zhen Li,
  • Chandra Mohan,
  • Carol Clayberger,
  • Edward K. Wakeland,
  • Shaheen Khan

DOI
https://doi.org/10.1038/s42003-024-07099-0
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Although significant progress has been achieved in elucidating the genetic architecture of systemic lupus erythematosus (SLE), identifying genes underlying the pathogenesis has been challenging. The NZM2410-derived lupus susceptibility Sle3 locus is associated with T cell hyperactivity and activated myeloid cells. However, candidate genes associated with these phenotypes have not been identified. Here, we narrow the Sle3 locus to a smaller genomic segment (Sle3k) and show that mice carrying Sle3k and Sle1 loci developed lupus nephritis. We identify Klf13 as the primary candidate gene that is associated with genome-wide transcription changes resulting in higher levels of proinflammatory cytokines, enhanced T cell activation, and hyperresponsiveness of myeloid cells. Correspondingly, Klf13 –/– mice display repression of genes involved in mediating immune activation, including key proinflammatory cytokines/chemokines in T cells and dysregulation in cytokine signaling pathways in myeloid cells in response to toll receptor ligands. Klf13 upregulation is associated with increased production of RANTES, a key chemokine in lupus nephritis, in activated T cells and the kidneys of lupus-prone mice. In sum, our findings reveal Klf13 as a key gene in the Sle3 interval in mediating lupus pathogenesis that may have implications in the rational design of new therapies for SLE.